pressrelease_332830_1568048728

Paras Biopharmaceuticals Successfully Develops Cytofold StructQuant® Technology for Cytoplasmic Disulphide Formation, (for Active Folding) for Complex Therapeutic Protein

oulu, Finland, September 10, 2019 --(PR.com)-- Paras Biopharmaceuticals Finland Oy is pleased to announce that its proprietary technology, Cytofold StructQuant®,...